NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
about
Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.NK cell heparanase controls tumor invasion and immune surveillance.Role of Distinct Natural Killer Cell Subsets in Anticancer Response.A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast CancerMolecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human TissuesHypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration
P2860
Q37737545-564675B6-5B34-4463-ABBF-6709AAC92603Q38701256-C602DA1A-D31A-47FC-95B5-57384809A0B8Q39210022-DC0E3AED-9915-4CFA-91DA-0873BBF62E80Q40620152-EF3B3A20-1BAA-4DAB-956E-377324882E29Q42056165-870358E6-25D0-4D3C-B805-4D8094213781Q47119391-6D4735B7-2B8E-48D1-9727-321CC26CEA58Q47156322-48EA989B-7189-4293-8604-A3503EB54A3CQ48136572-42C95C99-13C8-42F4-A625-CFC3C47A01D7Q55012882-DDE79694-42E4-422E-8D5F-F2E5B0D67428Q57462222-EA682074-CB04-406D-B29D-CEA18BF444EBQ58572875-F5A95423-FC63-4CBF-A629-49D6819A52F3Q59136348-86F968D5-85EC-4F27-9B4D-2A458976E09C
P2860
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@ast
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@en
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@nl
type
label
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@ast
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@en
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@nl
prefLabel
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@ast
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@en
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
NK Cells, Tumor Cell Transitio ...... ts for NK-Based Immunotherapy?
@en
P2093
Bianca Sparatore
Daniel Olive
Marco Pedrazzi
Maria Cristina Mingari
Monica Parodi
Segundo Gonzalez
P2860
P304
P3181
P356
10.1155/2016/4684268
P407
P50
P5008
P577
2016-05-12T00:00:00Z